Please login to the form below

Not currently logged in
Email:
Password:

Reata

This page shows the latest Reata news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: EU agencies brace for No Deal Brexit, GSK mulls spin-off, Realta scores in CKD

Daily Brief: EU agencies brace for No Deal Brexit, GSK mulls spin-off, Realta scores in CKD

Reata Pharma success in kidney disease treatment. Reata Pharmaceuticals has produced phase II results showing its bardoxolone methyl (bardoxolone) can prevent or dealy kidney failure in a rare form of chronic ... Reata collected historical eGFR data for

Latest news

  • Abbott stops kidney disease drug trial on safety concerns Abbott stops kidney disease drug trial on safety concerns

    Abbott Laboratories suffered a late-stage pipeline blow yesterday after partner Reata Pharmaceuticals was forced to halt all trials of a kidney disease drug on safety concerns. ... All other clinical trials of the drug have also been suspended and Reata

  • Abbott pays $110m for investigational kidney injury drug

    Bardoxolone is being developed in partnership with Reata Pharmaceuticals, while atrasentan was discovered in-house.

  • Abbott cuts 700 US jobs as it prepares for a major restructure

    Excluding these charges, as well as other one-off items, such as costs related to the company's Reata and Biotest collaborations, profits would have risen by 12.8 per cent,

  • Abbott agrees $400m chronic disease deal with Reata

    Abbott agrees $400m chronic disease deal with Reata. Will collaborate on oral treatments for pulmonary and central nervous system disorders and in immunology. ... For these conditions, Abbott will take 70 per cent of costs and profits, while Reata will

  • Regional plans

    A similar rationale applies to the deal between Abbott and Reata where Abbott will be providing the global marketing capability outside the US. ... Platform. 480. PregLem/Richter. Corporate acquisition. 461. Reata/Abbott. Bardoxolone for chronic kidney

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics